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ABSTRACT
Small/intermediate conductance KCa channels (KCa2/3) are
Ca2+/calmodulin regulated K+ channels that produce membrane
hyperpolarization and shape neurologic, epithelial, cardiovascu-
lar, and immunologic functions. Moreover, they emerged as
therapeutic targets to treat cardiovascular disease, chronic
inflammation, and some cancers. Here, we aimed to generate
a new pharmacophore for negative-gating modulation of KCa2/3
channels. We synthesized a series of mono- and dibenzoates and
identified three dibenzoates [1,3-phenylenebis(methylene) bis(3-
fluoro-4-hydroxybenzoate) (RA-2), 1,2-phenylenebis(methylene)
bis(3-fluoro-4-hydroxybenzoate), and 1,4-phenylenebis(methy-
lene) bis(3-fluoro-4-hydroxybenzoate)] with inhibitory efficacy as
determined by patch clamp. Among them, RA-2 was the most
drug-like and inhibited human KCa3.1 with an IC50 of 17 nM and
all three human KCa2 subtypes with similar potencies. RA-2 at
100 nM right-shifted the KCa3.1 concentration-response curve for
Ca21 activation. The positive-gating modulator naphtho[1,2-d]
thiazol-2-ylamine (SKA-31) reversed channel inhibition at nano-
molar RA-2 concentrations. RA-2 had no considerable blocking
effects on distantly related large-conductance KCa1.1, Kv1.2/1.3,
Kv7.4, hERG, or inwardly rectifying K1 channels. In isometric
myography on porcine coronary arteries, RA-2 inhibited bradykinin-
induced endothelium-derived hyperpolarization (EDH)–type relaxa-
tion in U46619-precontracted rings. Blood pressure telemetry in
mice showed that intraperitoneal application of RA-2 (# 100 mg/kg)
did not increase blood pressure or cause gross behavioral deficits.
However, RA-2 decreased heart rate by 145 beats per minute,
which was not seen in KCa3.1
2 /2 mice. In conclusion, we identified
the KCa2/3–negative-gating modulator, RA-2, as a new pharmaco-
phore with nanomolar potency. RA-2 may be of use to generate
structurally new types of negative-gating modulators that could
help to define the physiologic and pathomechanistic roles of KCa2/3
in the vasculature, central nervous system, and during inflammation
in vivo.
Introduction
Sm a ll-con du ct a n ce Ca 2+-a ct iva t ed K+ ch a n n els (KCa 2)
(Köhler et al., 1996; Adelman et al., 2012) and the intermediate-
conductance Ca2+-activa ted K+ channel (KCa3.1) (Ishii et a l.,
1997) a r e Ca 2+/ca lm odu lin (Ca M)-r egu la t ed a n d volt a ge-
independen t K+ cha nnels (Wei et a l., 2005). Their a ct iva t ion
pr oduces solid m em br a n e h yper pola r iza t ion t h a t in t u r n
in fluences elect r ica l excit a bilit y a nd sh a pes ca lciu m en t r y
through calcium-permeable channels. KCa2 channels (subtypes
2.1, 2.2, and 2.3) are expressed in excitable tissues such as
neurons, skeletal muscle, adrenal gland, and heart, and some
nonexcitable tissues such as the liver and vascular endothelium,
with varying subtype-specific tissue expression profiles (Wei
et al., 2005). In neurons, these channels underlie the apamin-
sensit ive medium afterhyperpolarization and regulate firing
frequency as well as learning and memory (Adelman et al.,
2012). In the cardiovascular system, KCa2 channels contribute to
cardiac repolarization (Li et al., 2009; Diness et al., 2010),
endothelium-der ived hyperpola r iza t ion (EDH)–t ype a r t er ia l
dila t ion in response to increased hemodynamics (Edwa rds
et a l., 2010; Milkau et a l., 2010; Wulff and Köhler , 2013), and
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provide negative feedback on sympathetic tone (Taylor et al.,
2003). With respect to pa thophysiologica l releva n t funct ions
in humans, recent evidence suggests a role, pa r t icular ly of
KCa2.3, in lone at r ia l fibr illa t ion (Diness et a l., 2010; Ellinor
et a l., 2010), cancer cell migra t ion and metastasis (Chantôme
et a l., 2013), and overact ive bladder (Soder et a l., 2013).
KCa3.1 channels are mostly expressed in nonexcitable t issues
such as red and white blood cell lineages, secretory epithelia,
and the vascular endothelium (Devor et al., 1996; Köhler et al.,
2000; Wei et a l., 2005; Wu lff a n d Köh ler , 2013). H er e,
h yper pola r iza t ion a n d K1 efflu x t h r ou gh Ca 21 -a ct iva t ed
KCa3.1 channels regulate cell volume regulat ion (Vandorpe
et al., 1998), flu id secret ion (Devor et a l., 1996), and—together
with KCa2.3 channels—EDH-type ar ter ia l dilat ion, specifica lly
t o a cet ylch olin e st im u la t ion (E dwa r ds et a l., 2010; Wu lff
a n d Köh ler , 2013). In it ia lly, KCa3.1 wa s believed t o be a n
exclusively nonneuronal channel (Ishii et a l., 1997; Wei et al.,
2005). However, recent evidence suggests possible expression
in cerebellar Purkinje cells in rats (Engbers et al., 2012) and
a role of the channel in behavior as suggested by the locomotor
hyperactivity in KCa3.1
2 /2 mice (Lambertsen et al., 2012). KCa3.1
channels have been patho-m echan ist ica lly implica ted in hu-
ma n disease such as ar terial endothelia l dysfunct ion (Félétou
et a l., 2010); cancer growth; cancer cell migrat ion, metastasis
(D’Alessandro et al., 2013), and neo-angiogenesis (Grgic et al.,
2005); organ fibrosis (Grgic et al., 2009); atherosclerosis (Toyama
et al., 2008); neointima formation (Köhler et al., 2003; Tharp
et al., 2008) and T cell responses (Wulff et al., 2007); and
microglia activity (Kaushal et al., 2007). For extensive in-depth
reviews, we refer the interested reader to Félétou et al. (2010),
Wulff and Castle (2010), and Wulff and Köhler (2013). Con-
sidering the patho-mechanistic roles of the channels, blockers of
KCa3.1 channels have emerged as potential drug candidates for
the t rea tmen t of sickle-cell disea se (Ata ga a nd Stocker ,
2009), immu nosuppression (Wulff and Castle, 2010), asthma
(Van Der Velden et al., 2013), fibrosis (Grgic et al., 2009),
atherosclerosis (Toyama et al., 2008), and cancer (Ruggieri et al.,
2012; D’Alessandro et al., 2013). Positive-gating modulators
(activators) of KCa3.1, such as naphtho[1,2-d]thiazol-2-ylamine
(SKA-31) (Sankaranarayanan et al., 2009) and 5-methylnaphtho
[2,1-d]oxazol-2-amine (SKA-121) (Coleman et al., 2014), may
improve endothelium-dependent vasodilat ion and lower blood
pressure (Sankaranarayanan et a l., 2009; Köhler et al., 2010;
Damkjaer et al., 2012; Mishra et al., 2013; Radtke et a l., 2013;
Wulff and Köhler , 2013). Act iva tors of KCa2 channels could be
useful to t reat epilepsy and ataxia (Shakkot ta i et a l., 2011),
while blockers may improve learning and memory. For a review,
see Lam et al. (2013).
The existing small molecule blockers of KCa3.1 and KCa2 chan-
nels are mainly pore blockers—e.g., for KCa3.1: 5-[(2-chlorophenyl)
(diphenyl)methyl]-1H-pyrazole (TRAM-34) (Wulff et al., 2001), 4-
[[3-(trifluoromethyl)phenyl]methyl]-2H-1,4-benzothiazin-3(4H)-one
(NS6180) (Strøbæk et a l., 2013), and ICA-17043 (Ataga and
Stocker , 2009) that obst ruct ion flow at the inner cavity of the
channel or a t the outer vest ibule, i.e., for KCa2: 6,10-dia za -3
(1,3)8,(1,4)-diben zen a -1,5(1,4)-diqu in olin a cyclodeca ph a n e
(UCL1684) (Rosa et a l., 1998). However, a caveat is tha t they
may enter the inner cavities of other channels and thereby
exer t unspecific effects a t h igh dosage. At 10 mM, a concentra-
t ion often used in cancer-rela ted studies, NS6180 inhibits
large-conductance KCa1.1 [maxi K], Kv1.3, and Kv11.1 (hERG)
by more than 50%, while TRAM-34 blocks Kv1.3, Kv1.4, Kv7.2 1
Kv7.3, and Nav1.4 (Strøbæk et a l., 2013). Clot r im a zole, a
r ela t ed KCa3.1 blocker a n d cytochrome P450 enzyme blocking
antifungal inhibits TRPM8 channels (Meseguer et al., 2008) with
submicromolar potencies, and has been shown to modulate
TRPV1 and TRPA1 channels t ha t act a s receptor s for noxius
hea t /pa in a nd ir r it a n t s, r espect ively, in nocicept ive neu rons
(Meseguer et a l., 2008), thus limiting the utility of these com-
pounds for studying KCa3.1 functions at the organ or systemic
levels. Therefore, negative-gating modulators of KCa2/3 channels,
which interfere with channel gating, could be advantageous over
the present pore blockers. To date, two negative-gating modulators,
(R)-N-(benzimidazol-2-yl)-1,2,3,4-tet rahydro-1-naphthylamine
(NS8593) (J enkins et al., 2011) and (–)-N-{7-[1-(4-tert-butyl-
phenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-N9-methoxy-
formamidine [(2 )-B-TPMF] (Hougaard et al., 2012) have been
described for KCa2 channels. Recently, our screening of a series
of phenols and polyphenols identified the synthetic fluoro-tri-
benzoic ester , 13b (Lamoral-Theys et a l., 2010) (F ig. 1A), as a
negative-gating modulator of KCa2/3 channels (Oliván-Viguera
et al., 2013). However, a disadvantage of 13b is that its high
molecular weight (582) and its log P value of 6.0 violate the
Lipinski et al. (2001) rule of five and make it unlikely that the
compound will have oral bioavailability. Moreover, the structure-
activity relationship accounting for channel inhibition has not
been characterized yet. Therefore, we decided to explore the
structure-activity relationship by synthesizing less lipophilic and
smaller analogs. Three compounds [1,3-phenylenebis(methylene)
bis(3-flu or o-4-hydr oxyben zoa t e) (RA-2), 1,2-ph en ylen ebis
(methylene) bis(3-fluoro-4-hydroxybenzoa te) (RA-3), a nd 1,4-
phenylenebis(methylene) bis(3-fluoro-4-hydroxybenzoate) (RA-4)]
(F ig. 1B) were identified as KCa2/3 pan inhibitors with negative-
gating modulator properties and potencies in the nanomolar
range. RA-2 inhibit ed EDH-t ype dila t ions in por cin e cor o-
na r y a r t er ies (P CAs) a n d wa s fou nd not t o in cr ea se blood
pressu r e in t elem et r y r ecor dings despit e r edu cin g hea r t
r a t e (HR).
Materials and Methods
Synt hesi s of M ono- and Di benzoat es. As shown in Fig. 1B,
monobenzoate benzyl 3-fluoro-4-hydroxybenzoate (RA-1) was obta ined
by reaction of benzylbromide with 3-fluoro-4-hydroxybenzoic acid. Dibenzoates
RA-2, RA-3, and RA-4 were obta ined by react ion of the corresponding
ABBREVIATIONS: BK, bradykinin; bs, broad singlet; CaM, calmodulin; d, doublet; dd, doublet of doublets; DMF, dimethylformamide; DMSO,
dimethyl sulfoxide; EDH, endothelium-derived hyperpolarization; ESI, electrospray ionization; HEK, human embryonic kidney; HR, heart rate;
HRMS, high-resolution mass spectra; IR, infrared; KCa, Ca
21 -activated K1 ; KCa2, small-conductance Ca
21 -activated K1 ; KCa3.1, intermediate-
conductance Ca21 -activated K1 ; m, multiplet; PCA, porcine coronary artery; PCAEC, porcine coronary artery endothelial cell; s, singlet; RA-1,
benzyl 3-fluoro-4-hydroxybenzoate; RA-2, 1,3-phenylenebis(methylene) bis(3-fluoro-4-hydroxybenzoate); RA-3, 1,2-phenylenebis(methylene) bis
(3-fluoro-4-hydroxybenzoate); RA-4, 1,4-phenylenebis(methylene) bis(3-fluoro-4-hydroxybenzoate); RA-5, 1,3-phenylenebis(methylene) bis(4-
acetamido-3-fluorobenzoate); RA-6, 5-(hydroxymethyl)-1,3-phenylene)bis(methylene) bis(3-fluoro-4-hydroxybenzoate); SKA-31, naphtho[1,2-d]
thiazol-2-ylamine; TRAM-34, 1-[(2-chlorophenyl) (diphenyl)methyl]-1H-pyrazole; U46619, (Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-hydroxyoct-1-enyl]-3-
oxabicyclo[2.2.1]heptan-6-yl]hept-5-enoic acid; WT, wild-type.















bis(bromomethyl)benzene with 3-fluoro-4-hydroxybenzoic acid. The dibenzoate
1,3-ph en ylen ebis(m et h ylen e) bis (4-a cet a m ido-3-flu or oben zoa t e)
(RA-5) wa s obt a in ed by r ea ct ion of 1,3-bis (br om om et h yl)benzene
with 3-fluoro-4-acetamidobenzoic acid. The dibenzoate 5-(hydroxymethyl)-
1,3-phenylene)bis(methylene) bis(3-fluoro-4-hydroxybenzoate) (RA-6) was
obtained by reaction of 1,3-bis(bromomethyl)-5-h ydr oxym et h ylben zen e
wit h 3-fluor o-4-h ydr oxyben zoic a cid. 3-F luor o-4-acet amidobenzoic
acid was obta ined by a cetyla t ion of 4-a mino-3-fluorobenzoic acid.
1,3-bis(bromomethyl)-5-hydroxymethylbenzene was prepared follow-
ing litera ture procedures (Díez-Barra et a l., 2001). All react ions were
performed in anhydrous dimethylformamide (DMF) a t 105°C using
sodium bicarbona te or potassium carbonate and yielded the corre-
sponding mono- or dibenzoa tes in 33–60% yields. Log P values were
calculated with the program ChemBioDraw-Ult ra-13.0 (PerkinElmer
Inc, Waltham, MA). Benzylbromide, 1,2-, 1,3-, and 1,4-bis(bromomethyl)
benzene, 4-amino-3-fluorobenzoic acid, and 3-fluoro-4-hydroxybenzoic
acid were purchased from Sigma-Aldr ich (St. Louis, MO), Alfa-Aesar
(Ward Hill, MA), or Fluorochem (Derbyshire, UK).
Gener al Pr ocedur es and Physi cal Data. Whenever possible,
the react ions were monitored by thin layer chromatography, which
was performed on precoated silica gel polyester pla tes. The products
were visualized using UV light (254 nm) or ethanolic phosphomolybdic
acid solution followed by heating. Column chromatography was performed
using silica gel (Kieselgel 60, 230–400 mesh; Sigma-Aldr ich). Melting
points were determined in open capillaries using a Gallenkamp
capillary melting point apparatus and were not corrected. Fourier
transform infrared (IR) spectra were recorded as KBr pellets using
a Thermo Nicolet Avatar 360 Fourier t ransform IR spectrometer
(Thermo Fisher Scientific Inc., Waltham, MA); nmax values expressed
in cm2 1 a re given for the main absorption bands. 1H NMR and
13C NMR spectra were acquired on a Bruker AV-400 (Wageningen UR,
The Netherlands) spectrometer operat ing at 400 MHz for 1H NMR,
100 MHz for 13C NMR, and 376 MHz for 19F NMR at room temperature
using a 5 mm probe. The chemica l shift s (d) are repor ted in par ts per
million and were referenced to the residual solvent peak. Coupling
constants (J) a re quoted in Hertz. The following abbreviat ions are used:
s, singlet ; d, doublet; m, multiplet ; bs, broad singlet ; and dd, doublet of
doublets. High-resolution mass spectra (HRMS) were recorded using
a Bruker Daltonics MicroToF-Q instrument from methanolic solut ions
unless otherwise indicated using the posit ive electrospray ionization
(ESI1 ) mode.
Synt hesi s of 4-Acet amido-3-Fluor obenzoi c Acid . A mixture of
4-amino-3-fluorobenzoic acid (233 mg, 1.5 mmol) and acetic anhydride
(459 mg, 425 ml, 4.5 mmol) in anhydrous pyridine (7 ml) was heated at
60°C overnight. Then, the mixture was concentrated in vacuo. Over the
residue, water (6 ml) was added and then the aqueous solution was
acidified with HCl 2N until pH 5 1. The product precipitated and was
collected by filtrat ion and dried providing 281 mg (95%) of compound
4-acetamido-3-fluorobenzoic acid as a slightly brownish solid. 1H NMR
(CD3OD, 400 MHz) d 2.20 (s, 3H), 7.74 (dd, 1H, J 5 11.5, J 5 1.8), 7.80
(doublet of doublets of doublets, 1H, J 5 8.5, J 5 1.8, J 5 0.9), 8.20
(dd, 1H, J 5 8.1, J 5 8.1); 13C NMR (CD3OD, 100 MHz) d 24.2, 117.3
(d, 21.1), 123.6, 127.1 (d, 3.1), 128.2, 132.2 (d, 11.3), 153.8 (d, 243.9),
167.8 (d, 2.6), 171.5; 19F NMR (CD3OD, 376 MHz) d -128.6.
Synt hesi s of RA-1. A mixture of benzylbromide (171 mg, 1 mmol),
3-fluoro-4-hydroxybenzoic acid (156 mg, 1.0 mmol), and NaHCO3
sodium (101 mg, 1.2 mmol) in anhydrous DMF (15 ml) under an argon
atmosphere was heated at 105°C under argon a tmosphere overnight .
The mixture was cooled and then satura ted aqueous NaHCO3 (7 ml),
sa turated aqueous NaCl (10 ml), and AcOEt (50 ml) were added. The
mixture was filtered through a pad of Celite and after decanta t ion the
aqueous layer was extracted with AcOEt (2 20 ml). The combined
organic layers were dr ied over anhydrous MgSO4 and concentra ted in
vacuo. Finally, the crude product was purified by silica gel column
chromatography (eluent : AcOEt/hexane, 1:3) to afford 147 mg (60%) of
compound RA-1 as a white solid. M.p. 93–94°C; IR (KBr): wave
number (nmax) 5 3330, 1684, 1621, 1592, 1522;
1H NMR (CDCl3,
400 MHz) d 5.35 (s, 2H), 6.20 (bs, 1H), 7.00–7.07 (m, 1H), 7.32–7.48 (m,
5H), 7.78–7.83 (m, 2H); 13C NMR (CDCl3, 100 MHz) d 66.9, 117.0
(d, J 5 2.0), 117.2 (d, J 5 19.6), 122.9 (d, J 5 6.0), 127.2 (d, J 5 3.2), 128.2,
128.3, 128.6, 135.8, 148.2 (d, J 5 14.2), 150.4 (d, J 5 237.6), 165.5
(d, J 5 2.8); 19F NMR (CDCl3, 376 MHz) d -139.7; HRMS (ESI
1 ):
ca lcu la ted for C14H11FNaO3 [M 1 Na]
1 269.0584; found 269.0559.
Gener al Pr ocedur e for t he Synthesi s of Bi s(3-f luor o-4-
hydr oxybenzoates) f r om Dibr omomethy lbenzene Der i vat i ves.
A mixture of the corresponding dibromide der iva te (1.0 mmol),
3-fluoro-4-hydroxybenzoic acid (343 mg, 2.2 mmol), and NaHCO3 (210 mg,
2.5 mmol) in a nhydrous DMF (15 ml) under an a rgon a tmosphere
was hea ted a t 105°C overnigh t . The mixtu re was cooled and then
sa tura ted aqueous Na HCO3 (7 ml), sa tu ra t ed a queous NaCl (10 ml),
and AcOEt (50 ml) were added. The mixture was filtered through a pad of
Celite and after decantation the aqueous layer was extracted with AcOEt
(2 20 ml). The combined organic layers were dried over anhydrous
MgSO4 and concentrated in vacuo. Finally, the crude product was purified
by silica gel column chromatography (eluent: AcOEt/hexane, 1:3).
RA-2. Applica tion of the genera l procedure to 1,3-bis(bromomethyl)
benzene and 3-fluoro-4-hydroxybenzoic acid afforded 145 mg (35%) of
compound RA-2 as a white solid. M.p. 165–166°C; IR (KBr): nmax 5
3250, 1700, 1616, 1597, 1517; 1H NMR (CD3OD, 400 MHz) d 5.27
Fig. 1. Synthesis, st ructures, and selected propert ies of mono- and difluoro
benzoates. (A) Structure of the paren t compound, 13b. (B) Scheme of the
synthesis and structures of RA-1 to RA-6, together with molecula r weights
and log P values.















(s, 4H), 6.85–6.95 (m, 2H), 7.34–7.35 (m, 3H), 7.46 (bs, 1H), 7.60–7.70
(m, 4H); 13C NMR (CD3OD, 100 MHz) d 67.3, 118.3 (d, J 5 20.0), 118.4
(d, J 5 3.0), 122.6 (d, J 5 6.0), 127.9 (d, J 5 3.0), 128.6, 128.8, 129.9,
138.1, 151.3 (d, J 5 12.9), 152.2 (d, J 5 240.3), 166.8 (d, J 5 2.7); 19F NMR
(CD3OD, 376 MHz) d -138.7; HRMS (ESI
1): calculated for C22H16F2NaO6
[M 1 Na]1 437.0807; found 437.0787.
RA-3. Applica t ion of genera l procedure to 1,2-bis(bromomethyl)
benzene and 3-fluoro-4-hydroxybenzoic acid afforded 156 mg (38%) of
compound RA-3 as a white solid. M.p. 207–208°C; IR (KBr): nmax 5
3281, 1703, 1619, 1523; 1H NMR (CD3OD, 400MHz) d 5.45 (s, 4H),
6.80–6.90 (m, 2H), 7.35–7.45 (m, 2H), 7.48–7.53 (m, 2H), 7.54–7.60
(m, 4H); 13C NMR (CD3OD, 100 MHz) d 65.5, 118.2 (d, J 5 20.0), 118.4
(d, J 5 3.0), 122.5 (d, J 5 6.0), 127.9 (d, J 5 3.0), 130.0, 131.4, 136.3,
151.5 (d, J 5 12.9), 152.2 (d, J 5 240.3), 166.8 (d, J 5 2.7); 19F NMR
(CD3OD, 376 MHz) d -138.6; HRMS (ESI
1 ): calculated for C22H16F2NaO6
[M1 Na]1 437.0807; found 437.0809.
RA-4. Applica t ion of genera l procedure to 1,4-bis(bromomethyl)
benzene and 3-fluoro-4-hydroxybenzoic acid afforded 138 mg (33%) of
compound RA-4 as a white solid. M.p. 212–213°C; IR (KBr): nmax 5
3269, 1684, 1617, 1600, 1530; 1H NMR (CD3OD, 400 MHz) d 5.27
(s, 4H), 6.90–6.95 (m, 2H), 7.41 (s, 4H), 7.60–7.70 (m, 4H); 13C NMR
(CD3OD, 100 MHz) d 67.3, 118.3 (d, J 5 19.9), 118.5 (d, J 5 3.0), 122.6
(d, J 5 6.0), 127.9 (d, J 5 3.0), 129.4, 137.6, 151.4 (d, J 5 12.8), 152.3
(d, J 5 240.3), 166.9 (d, J 5 2.6); 19F NMR (CD3OD, 376 MHz) d -138.5;
HRMS (ESI1 ): ca lculated for C22H16F 2NaO6 [M1 Na]
1 437.0807;
found 437.0807.
RA-6. Application of general procedure for the synthesis of esters from
bromide derivatives to 1,3-bis(bromomethyl)-5-hydroxymethylbenzene
and 3-fluoro-4-hydroxybenzoic acid afforded 125 mg (28%) of com-
pound RA-6 as a white solid. 1H NMR (CD3OD, 400 MHz) d 4.63 (s, 2H),
5.31 (s, 4H), 6.90–6.95 (m, 2H), 7.38–7.42 (m, 3H), 7.60–7.70 (m, 4H);
13C NMR (CD3OD, 100 MHz) d 64.8, 67.4, 118.3 (d, J 5 20.0), 118.5
(d, J 5 3.0), 122.7 (d, J 5 6.0), 127.4, 127.5, 128.0 (d, J 5 3.0), 138.3,
143.8, 151.4 (d, J 5 12.8), 152.3 (d, J 5 240.3), 166.8 (d, J 5 2.7);
19F NMR (CD3OD, 376 MHz) d -138.5.
Synthesi s of RA-5. A mixture of 1,3-bis(bromomethyl)benzene
(132 mg, 0.5 mmol), 4-acetamido-3-fluorobenzoic acid (217 mg, 1.1 mmol)
and K2CO3 (173 mg, 1.25 mmol) in anhydrous DMF (7 ml) under an
argon atmosphere was heated at 105°C overnight. The mixture was
cooled and then saturated aqueous NaHCO3 (3 ml), saturated aqueous
NaCl (5 ml), and AcOEt (25 ml) were added. The obtained mixture was
filtered through a pad of Celite and after decantation the aqueous layer
was extracted with AcOEt (2 10 ml). The combined organic layers
were dried over anhydrous MgSO4 and concentrated in vacuo. Re-
crystallization from methanol afforded 123 mg (50%) of the compound
RA-5 as a brownish solid. M.p. 190–191°C; IR (KBr): nmax 5 3305, 3262,
3192, 1719, 1676, 1620, 1607, 1541; 1H NMR (CD3OD, 400 MHz) d 2.14
(s, 6H), 5.36 (s, 4H), 7.42–7.45 (m, 3H), 7.56 (bs, 1H), 7.70–7.80 (m, 4H),
8.23 (dd, 2H, J 5 8.1, J 5 8.1), 10.03 (bs, 2H); 13C NMR (CD3OD,
100 MHz) d 23.7, 66.0, 115.9 (d, J 5 21.2), 122.2, 124.9 (d, J 5 6.9), 125.8
(d, J 5 2.9), 127.2, 127.6, 128.7, 131.3 (d, J 5 11.1), 136.3, 151.8 (d, J 5
244.1), 164.2 (d, J 5 2.5), 169.2; 19F NMR (CD3OD, 376 MHz) d -124.7;
HRMS (ESI1 ) (from DMF solu tion): calculated for C26H22F2N2NaO6
[M 1 Na]1 519.1338; found 519.1307.
Cel l L i nes. Human embryonic kidney cells (HEK293) stably
expressing hKCa3.1 (a kind gift from Dr. Khaled M. Houamed,
Un iver sity of Chicago) (Cao and Houa med, 1999); hKv1.2-B82 cells
(Wer kman et a l., 1992); mKv1.3-L929 cells (Gr issmer et a l., 1994);
hKv7.4-HEK293 (a kind gift from Nicole Schmitt, University Copenhagen,
Denmark); hERG-HEK293 (a kind gift from Craig J anuary, Univer-
sity of Wisconsin, Madison, WI); hKCa2.1-HEK293 cells and rKCa2.2-
HEK293 cells; hKCa2.3-COS7 cells (Sankaranarayanan et a l., 2009);
3T3 fibroblasts (3T3-L1, ref# CL-173, American Type Culture Collection,
Rockville, MD); U251 glioblastoma cells; and primary PCA endothelial
cells (PCAECs) were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% feta l ca lf serum and penicillin /st reptomycin
(a ll from Biochrom KG, Berlin , Germany). The PCAECs were isolated
from hear ts as described previously (Oliván-Viguera et al., 2013).
Hear ts were kindly provided by the local abattoir (Mercazaragoza,
Zaragoza). Pr ior to patch-clamp experimenta tion, cells were t rypsin-
ized, seeded on cover slips in a NaCl bath solution (see below), and used
for electrophysiological measurements with in the same day.
Compounds and Chemicals. Compounds for synthesis and
exper imentat ion were purchased from Sigma-Aldr ich, Tocr is (Bristol,
United Kingdom), Fluorochem, or Alfa Aesar . TRAM-34 (Wulff et a l.,
2000) and SKA-31 (Sankaranarayanan et a l., 2009) were synthesized
in the Wulff laboratory (Pharmacology, University of California at
Davis, Davis, CA). Stock solut ions (a t 1 or 10 mM) of a ll compounds
were prepared with dimethylsulfoxide (DMSO). The final DMSO
concentra t ion did not exceed 0.5% in single exper iments test ing one or
more compounds.
Pat ch -Cl am p El ect r op h ysi ol ogy . In side-ou t a n d wh ole-cell
membrane currents were recorded using an EPC10-USB patch-clamp
amplifier (HEKA Electronics, Lambrecht/Pfa lz, Germany), U-ramps
(2 100 to 100 mV, 1 second), and Patchmaster software (HEKA Elec-
tronics) as descr ibed in more deta il previously (Oliván-Viguera et a l.,
2013). The amplitudes of K1 -outward currents were measured at 0 mV.
For measurements of hERG currents, we used a prepulse to 2 80 mV
(1 second), a depolar izing pulse to 1 30 mV (1 second), and a pulse
to 2 40 mV (1 second). Leak subtraction was omitted during data
acquisition, a lthough ohmic leak was subtracted if appropr ia te. In fast
whole-cell exper iments on KCa channels, the K-pipette solut ion was
composed of (in mM): 140 KCl, 1 MgCl2, 2 EGTA, 1.71 CaCl2 (1 mM
[Ca21 ]free) and 5 HEPES (adjusted to pH 7.2 with KOH). For measuring
voltage-gated K1 channels, the pipette solution conta ined 100 nM
[Ca21 ]free (2 mM EGTA, 0.7 mM CaCl2). The NaCl bath solution was
composed of (mM): 140 NaCl, 5 KCl, 1 MgSO4, 1 CaCl2, 10 glucose, and
10 HEP ES (adjust ed to pH 5 7.4 with NaOH). F or ca lcula t ion of
the IC50 va lues, da ta poin t s were fit t ed using the dose-response
equa t ion : y 5 A2 1 ðA1 2 A2Þ=½1 1 ðx=x0Þp or the Bolt zmann equa-
t ion : y 5 A2 1 ðA1 2 A2Þ=½1 1 expðx 2 x0=dxÞ. The inside-out exper i-
ments on hKCa3.1 shown in Fig. 2D were performed in symmetr ical K
1 .
The extracellular solut ions conta ined (in mM): 154 KCl, 10 HEPES
(pH 5 7.4), 2 CaCl2, 1 MgCl2. Solutions on the int racellular side con-
ta ined (in mM): 154 KCl, 10 HEPES (pH 5 7.2), 10 EGTA, 1.75 MgCl2,
and CaCl2 to yield calculated free Ca
21 concent ra tions of 0.05, 0.1, 0.25,
0.3, 0.5, 1, 10, and 30 mM. Free Ca21 concentrations were calculated
with the MaxChelator program (http://maxchelator.stanford.edu/) as-
suming a temperature of 25°C, a pH of 7.2, and an ionic st rength of
160 mM. Cells were clamped to a holding potent ial of 0 mV and KCa
currents were measured using 200 millisecond voltage ramps from 2 80
to 80 mV applied every 5 seconds.
M yogr aphy on PCAs. Isometric myography on PCA rings was
done as described in detail previously (Alda et al., 2009; Valero et al.,
2011). In brief, rings of arteries were mounted onto an isometric force
transducer (Pioden UF1, Graham Bell House, Canterbury, UK). The
bath containing Krebs buffer (37°C; equilibrated with 95% O2/5% CO2)
consisted of (in mM): NaCl 120, NaHCO3 24.5, CaCl2 2.4, KCl 4.7, MgSO4
1.2, KH2PO4 1, and glucose 5.6, pH 5 7.4. Rings were prestretched to an
initial tension of 1 g (10 mN). Changes in force were registered using
a Mac Laboratory System/8e program (AD Instruments, Inc., Milford,
MA) at a sample rate of 0.5 seconds. To analyze EDH-type relaxation, the
buffer contained the NO-synthase blocker, Nv -nitro-L-arginine (L-NNA,
300 mM), and the cyclooxygenase blocker , indomethacin (10 mM). Rings
were precontracted with the vasospasmic thromboxane analog, (Z)-7-
[(1S,4R,5R,6S)-5-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxabicyclo[2.2.1]heptan-
6-yl]hept-5-enoic acid (U46619) (0.2 mM) in the presence of RA-2 or its
vehicle DMSO, followed by relaxation with BK (1 mM). Thereafter, rings
were fully contracted with KCl (60 mM) buffer for 10 minutes, followed
by addition of sodium nitroprusside (10 mM) to produce endothelium-
independent relaxation.
Stock solut ions of compounds were made in DMSO and appropr ia te
amounts were added to the bath . Other compounds were dissolved in
Milli-Q water . Data analysis: Relaxat ions were determined as per-
centage change of precontract ion and rela t ive to the tota lly relaxed
sta te (absence of the contract ing agent).















Blood Pr essur e Telemet r y. Telemetry was performed as de-
scr ibed previously (Brähler et a l., 2009; Radtke et a l., 2013). Animal
protocols were in accordance with Animal Research: Report ing of In
Vivo Exper iments guidelines and approved by the Inst itu t ional
Animal Care and Use Commit tee of the University of Zaragoza and
IACS (Comisión Ét ica Asesora [CEA]; permit no. PI01/13). In br ief,
TA11PA-C10 pressure t ransducers (Data Sciences Internat ional,
St . Paul, MN) were implanted into the left ca rot id ar tery of four
adult female wild-type (WT) and three adult female KCa3.1
2 /2
(Brähler et a l., 2009) under deep anesthesia as descr ibed previously
(Radtke et a l., 2013). Mice were a llowed to recover for 10 days unt il
reaching normal day night rhythm. Mice had free access to tap water
and standard chow. Telemetry data were recorded over 1 minute
every 10 minutes over 24 hours and averaged. Data were analyzed
using the Data Sciences Internat ional software.
The compound or vehicle (peanut oil) was injected during the third
hour of the dark phase (activity phase) and we collected telemetry data
after 20–30 minutes after injection. To minimize stress and pain caused
by intraperitoneal injections, mice were briefly anesthetized by isoflurane
inhalation. After a first injection, animals were reused for injections of
a higher dose of RA-2 or vehicle. Preparation and injection of RA-2:
Appropriate amounts of RA-2 were dissolved in warmed peanut oil
(Sigma-Aldrich) to give a dose of 3, 30, or 100 mg/kg. Injection volume was
# 600 ml.
Phar macok inet i cs. RA-2 wa s d issolved in pea n u t oil a n d
30 mg/kg were administered int raper itoneally to female C57Bl6J
mice (20–30 g, 3–5 month old, n 5 3 per t ime point ) as descr ibed
above. Mice were sacr ificed at 1, 2, 4, 8, 24, or 48 hours after inject ion.
Blood was taken by puncture of the r ight ventr icle under CO2
anesthesia (permit no. PI01/13), t ransferred into EDTA-containing
tubes, and stored on ice unt il fur ther processing. EDTA-blood was
centr ifuged a t 1000g for 10 minutes and 4°C and plasma was stored at
2 20°C. Tissue samples (liver , bra in , and femoral skeleta l muscle)
were excised, frozen, and stored a t 2 20°C unt il use.
Plasma (50 ml) was added to 950 ml acetonit r ile, vor texed and
centr ifuged at 13,500g for 30 minutes at room temperature to
precipita te the protein . The superna tant was t ransferred to a 4 ml
via l, concentra ted to dryness and reconst ituted with acetonit r ile to
150 ml. Tissue samples (200 mg) were homogenized in 1 ml of H2O
with a Brinkman Kinemat ica PT 1600E homogenizer (Brinkman
Kinemat ica , Eschbach, Germany) and protein precipita ted with 1 ml
of acetonit r ile. The samples were then centr ifuged at 13,500g for
Fi g. 2. Negat ive-ga t ing modulat ion of KCa2/3 channels by RA-2. (A) Left panel: inside-out patch-clamp exper iments showing concentra t ion-dependent
inhibit ion of cloned hKCa3.1. (B) Left panel: inhibit ion of cloned hKCa2.3. Right panels (A and B): concentra t ion-response curves. Data points (mean 6
S.E .M.; KCa3.1: n = 4–10, exper iments for each concent ra t ion; KCa2.3: n = 2–12, exper iments each) were fit ted with the Boltzmann equa t ion (A) or the
dose-response equat ion (B). (C) The posit ive-ga t ing modula tor SKA-31 (1 mM) reversed KCa3.1 channel inhibit ion at nanomolar (left panel) bu t not a t
micromolar concent ra t ions of RA-2 (r ight panel). Lower panel: quant ita t ive da ta (mean 6 S.E.M.; n = 3, exper iments for each concent ra t ion). (D) Left and
middle panels: represen ta t ive currents from inside-out pa tches in the presence of 500 nM (top) and 30 mM (bot tom) int racellu lar Ca2+ before and after
applica t ion of 100 nM of RA-2. Right panel: Ca2+-concent ra t ion response curve for KCa3.1 act ivat ion measured from inside-out pa tches in the absence or
presence of 100 nM RA-2. Currents from individual pa tches were norm alized to the effect of 10 mM Ca 2+ in the absence of RA-2. Data are mean 6 S.D.
(n = 3, exper iments per data point ).















30 minutes. The supernatants were concent ra ted to dryness and
reconstituted in 200 ml of acetonit r ile. Liquid chromatography and
mass spect rometry analysis was performed with a Waters Acquity
UPLC (Waters, New York) equipped with a Acquity UPLC BEH 1.7 mm
RP-8, 2.1 150 mm column (Waters) interfaced to a TSQ Quantum
Access Max mass spectrometer (ThermoFisher Scientific, Waltham,
MA). U sin g a n a t m osph er ic pr essu r e ch em ica l ion iza t ion m a ss
spectrometer and selective reaction monitoring (capillary temperature
327°C, vaporization temperature 350°C, collision energy 38 eV, negative
ion mode), RA-2 was quantified by its base peak of 110.2 m/ z and its
concentration was calculated with a four-point ca libration curve from
10 nM to 1 mM. The mobile phase consisted of acetonitrile and water,
both conta ining 0.2% acetic acid with a flow rate of 0.300 ml/min. The
gradient was ramped from 95/5 water/acetonitr ile to 5/95 acetonitrile/
water over 2 minutes and returned to 95/5 water/acetonitrile after
6 minutes. RA-2 was introduced onto the column with an in jection
volume of 6 ml. Using these conditions, RA-2 had a retention time of 3.78
minutes. Liver metabolites were analyzed under full scan mode without
collision energy with a mass range of 1502 1500 m/ z. The mobile phase
consisted of an isocra tic gradient (90/10 acetonitr ile/water). Under these
conditions, RA-2 had a retention time of 1.76 minutes and liver metabolites
eluted at 1.74, 2.71, and 3.11 minutes.
Stat i st i cs. Data are given as mean 6 S.E.M. if not sta ted otherwise.
For comparison of data sets we used the unpaired Student ’s t test or one-
way analysis of variance followed by the Tukey post hoc test in the case
of multiple comparisons. P values of , 0.05 were considered significant.
Results
We previously identified 13b (Fig. 1A) as a negative-gating
modulator of KCa2/3 channels (Oliván-Viguera et al., 2013).
However, 13b’s drug likeness is poor because of its high mo-
lecular weight and high lipophilicity, limiting its in vivo bio-
availability. Therefore, we synthesized a series of smaller and
less lipophilic mono- and dibenzoates that met Lipinski’s rule of
five for a drug-like compound (Lipinski et al., 2001) (Fig. 1). RA-1,
RA-2, RA-3, RA-4, and RA-6 (Fig. 1B) were obta ined from the
corresponding mono- or dibromide-3-fluoro-4-hydroxybenzoic acid.
RA-5 was obta ined from 1,3-bis(bromom ethyl)benzene and
4-acetamido-3-fluorobenzoic acid, which in turn was obta ined
by acetyla tion of 4-amino-3-fluorobenzoic acid.
Elect r ophysi ology. We performed inside-out and whole-
cell pa tch-clamp exper iments on cloned hKCa3.1 and hKCa2.3
as well as nat ive KCa3.1/KCa2 in PCAECs and a ser ies of
distant ly rela ted K channels to test efficacy and select ivity.
Removal of lipophilic branches from the parent compound
led to the following result s: Compound RA-1 with only one
benzoa te r ing had no considerable inhibitory act ivity on
KCa3.1 (Table 1). The 1,3-dibenzoa te RA-2 was a potent
KCa3.1 and KCa2.3 inhibitor with IC50 values of 17 6 3 nM and
2 6 1 nM as determined in inside-out recordings on hKCa3.1 in
HEK-293 cells and hKCa2.3 in COS7 cells (Fig. 2, A and B; for
numeric data , see Supplementa l Table 1 and Table 1). RA-2
simila r ly inhibited cloned hKCa2.1 and rKCa2.2 at nanomolar
concentra t ions (Supplementa l Table 1). We obta ined simila r
IC50 va lues in whole-cell exper iments on murine KCa3.1
expressed in 3T3-fibroblast s (Supplementa l Fig. 1A). The 1,2-
a n d 1,4-d iben zoa t e der iva t ives , RA-3 a n d RA-4, sh owed
a similar potency with an IC50 value for RA-3 of 6 6 2 nM
(Supplementa l Fig. 1B; Table 1). Compound RA-5, in which
the hydroxyl group on the benzoic acid moiety had been
substituted by an acetamido group (Fig. 1B), had no considerable
inhibitory activity (Table 1). Introduction of a hydroxymethyl
substituent in the 5-position of the central aromatic core (RA-6,
Fig. 1B) led to a loss of activity (Table 1). It is noteworthy that
3-fluorobenzoic moiet ies (4-h ydroxy-3-fluorobenzoic acid and
4-amino-3-fluorobenzoic acid) and 1,3-phenylenedimethanol as
potent ial metabolites of RA-2/RA-5 hydrolysis, respect ively, did
not modify KCa3.1 currents.
Simila r to our previous observat ions with the template 13b
(Oliván-Viguera et a l., 2013), we found tha t the posit ive-
ga t ing modula tor , SKA-31, was capable of reversing the
inhibit ion caused by nanomolar but not micromolar concen-
t ra t ions of RA-2 (F ig. 2C). This suggested (1) antagonism of
the two compounds; (2) inhibitory act ions of RA-2 simila r to
tha t of 13b; and (3) tha t RA-2 acted as a negat ive-ga t ing
modula tor again simila r to 13b (Oliván-Viguera et a l., 2013).
To determine if the effects of RA-2 were Ca21 dependent as
was the case with previously described nega tive-gat ing mod-
ula tors such as NS8593 and its deriva tives (J enkins et a l.,
2011), we performed inside-out experiments, in which we
varied the int racellular [Ca21 ]i concent ra tion and investigated
the ability of 100 nM of RA-2 to inhibit KCa3.1 currents. As
shown in Fig. 2D, 100 nM of RA-2 near ly completely inhibited
t h e cu r r en t e licit ed by 500 n M [Ca 21 ]i, wh ile t h e sa m e
concentrat ion had a smaller effect in the presence of satura ting
30 mM [Ca21 ]i. Ca
21 concentrat ion-response curves obtained in
the presence and absence of 100 nM of RA-2 (Fig. 2D, right-
hand side) revealed tha t RA-2 shifted the curve to the r igh t but
also reduced the maximal current at 30 mM, suggest ing that
the compound exer ted negative-gating modula tion of KCa3.1.
With respect to select ivity, we found tha t RA-2 had no
considerable inhibitory or act iva t ing effects a t a concentra t ion
of 1 mM on the distant ly rela ted human KCa1.1 channel in
TABLE 1
Inhibitory efficacy of mono- and difluorobenzoa tes on hKCa3.1
Da ta a re der ived from inside-ou t pa tch -clam p exper iment s on hKCa3.1 sta bly expressed in HEK293 cells. Da ta ar e given as
mea n 6 S.E .M., n $ 3.
Compound IC50 Cont rol a t 1 mM Control a t 5 mM Control a t 10 mM
%
4-Amino-3-fluorobenzoic acid NT NT 90 6 3
4-Hydroxy-3-fluorobenzoic acid NT NT 80 6 8
1,3-Phenylenedimethanol NT NT 106 6 8
RA-1 94 6 1 87 6 2 NT
RA-2 17 6 3 nM 4 6 1 NT NT
RA-3 6 6 2 nM 12 6 2 2 6 1 NT
RA-4 15 6 6 NT NT
RA-5 97 6 2 94 6 1 NT
RA-6 83 6 3 74 6 11 NT
NT, not tested.















U251 glioblastoma cells; cloned Kv1.2, Kv1.3, and Kv7.4
channels; the important cardiac hERG channels (Kv11.1); or
na t ive inwardly rect ifying K1 channels in U251 cells. The
da ta are summarized in Supplementa l Table 1 and represen-
ta t ive recordings are shown in Supplementa l F igure 2.
Patch Clamp on Por ci ne Cor onar y Endothel i um and
I somet r i c M yogr aphy. Consider ing RA-2 as one of the
drug-like compounds of th is ser ies, we cont inued evaluat ing
funct ional act ivity in an ex vivo test system, i.e., PCAs
(Oliván-Viguera et a l., 2013), in which KCa2/3 channels have
been suggested to init ia te—a t least in par t (Ge et a l., 2000)—
the so-ca lled EDH-type of endothelium-dependent vasorelax-
a t ion (Edwards et a l., 2010). In the present study, we first
measured endogenous KCa2 and KCa3.1 currents in freshly
isola ted PCAEC and we found that 1 mM RA-2 vir tua lly
abolished SKA-31–act iva ted composite KCa2/KCa3.1 curren ts
and also fully inhibited the TRAM-34–insensitive KCa2-mediated
current in these cells (Fig. 3A).
Our isomet ric myography exper iments in the presence of
blockers of NO and prostacyclin synthesis (to specifica lly study
EDH-type relaxat ion) showed tha t RA-2 at 1 mM did not
modula te basal tone in these ar ter ies (data not shown).
However , RA-2 almost abolished the BK-induced relaxat ion
in r ings being strongly precontracted with a vasospasmic
agent , the thromboxane analog, U46619 (F ig. 3B). RA-2 did
not modulate sodium nit roprusside–induced and endothelium-
independent relaxation of 60 mM KCl-contracted r ings (data
not shown). Taken together, RA-2 showed act ivity in PCAs by
inhibit ing EDH-type endothelium-dependent relaxat ion .
Syst emi c Car di ovascu lar Ef fect s of RA-2. In keeping
with the expression of KCa3.1 and KCa2.3 channels in the
vascular endothelium and their proposed roles in systemic
cardiovascular regula t ion (Brähler et a l., 2009), we next
evaluated cardiovascula r act ivity and select ivity of the pan-
KCa2/3–negat ive-ga t ing modula tor , RA-2, by blood pressure
telemetry in WT and KCa3.1
2 /2 mice (Brähler et a l., 2009). If
compared with the vehicle, in t raper itoneal in ject ions of 3, 30,
or 100 mg/kg RA-2 did not significant ly change mean ar ter ia l
blood pressure over 24 hours in the WT mice (F ig. 4A, for
30 mg/kg, and Supplementa l F ig. 3A, for 3 and 100 mg/kg).
However , RA-2 at 30 and 100 mg/kg significant ly reduced HR.
The reduct ion in HR star ted apparent ly 30–60 minutes after
in ject ion and reached lowest levels ( D145 bea ts per minute)
a t the end of the act ivity phase and during the rest ing phase
(Fig. 4B; Supplementa l F ig. 3A, lower-r ight panel). RA-2 a t
the lower dose of 3 mg/kg produced a smaller reduction in HR
(Supplemental Fig. 3A, lower-left panel). Besides the lower HR,
wave forms were similar in the presence or absence of RA-2 and
are shown in Supplemental Fig. 3B.
We next evaluated to which extent the HR reducing effects
of RA-2 in the WT mice depended on KCa3.1 channels and
performed telemetry in KCa3.1
2 /2 mice. Similar to WT mice,
RA-2 at 30 mg/kg did not change the mean arterial blood
pressure in the KCa3.1
2 /2 mice (Fig. 4C, left-hand side). However,
we did not find a reduction in HR in KCa3.1
2 /2 mice (P , 0.05;
Fig. 4D, right-hand side). Together, the telemetric monitoring
revealed that RA-2 had no gross deleterious effects on blood
pressure. Nonetheless, it is noteworthy that RA-2 reduced HR in
a KCa3.1-dependent manner.
Phar macok i net i cs of RA-2. Analysis of tissue concentra-
tions and distribution of RA-2 in plasma, brain, skeletal muscle,
fat, and liver by a combination of ultra-high performance liquid
Fi g. 3. Negative-ga ting modulation of endogenous KCa3.1 and KCa2.3 channels in porcine endothelium and RA-2–evoked modulat ion of arter ia l contraction
and relaxa tion of the PCA. (A) Left panel: potentiat ion of KCa2/KCa3.1 from preactivation levels (during infusion of 1 mM Ca
2+) by 1 mM SKA-31 followed by
current inhibit ion by 1 mM RA-2. Middle panel: par tial inhibit ion of SKA-31–poten tiated current by 1 mM TRAM-34 followed by complete inhibit ion of the
TRAM-34–insensit ive component by 1 mM RA-2. Right panel: summary da ta . Data points a re mean 6 S.E .M. (n = 3-8, a rter ies for each compound). *P , 0.01
SKA-31 versus Ctr l (without compounds); #P , 0.05; SKA-31 versus TRAM-34, RA-2, or TRAM-34 and RA-2; Student ’s t test . (B) RA-2 inhibited BK (1 mM)-
induced relaxa tion in r ings st rongly precont racted with U46619 (0.2 mM). Data points a re mean 6 S.E.M. (n = 5–6, arter ies each); **P , 0.01.















chromatography and mass spectrometry (Fig. 5A) revealed that
RA-2 plasma concentration was 136 nM at 1 hour after injection
and 18 nM at 2 hours after injection, and that the compound was
not detectable at later t ime points (Fig. 5B). RA-2 went rapidly
into tissue (skeletal muscle, brain, and fat), where at 1 hour it
reached concentrations of 1.7 mM (skeletal muscle), 91 nM
(brain), and 6 mM (fat) (Fig. 5, C and D). As expected for an ester,
RA-2 was rapidly cleared from the circulating blood within
1 hour (F ig. 5B), presumably via hydrolysis by pla sma and
hepa t ic est era ses as indica ted by the a bsence of RA-2 in liver
and high amounts of possible metabolites in this tissue (Fig. 6).
Compounds with the masses shown in Fig. 6 were identified in
liver homogenate and were present in estimated concentrations
of 1 to approximately 50 mM but could not be precisely quantified
without reference compounds. The metabolites were likely
eliminated via the bile since metabolites were not detectable in
plasma at the same time point. In conclusion, intraperitoneal
administration of RA-2 yielded tissue concentrations above the
IC50 value for channel inhibition for 1–2 hours that fairly
corresponded to the beginning of bradycardia (Fig. 4).
Discussion
The purpose of the present study was to synthesize potent and
structurally novel pharmacophores for negative-gating modula-
tion of KCa2/3 channels. We succeeded in identifying three fluoro-
dibenzoates that inhibited KCa2/3 channels in the low nanomolar
ra nge and in a Ca 21 -concen t r a t ion-dependen t ma nner a nd
exhibited antagonism with a positive-gating modulator. The
most drug-like compound RA-2 inhibited KCa2/3-initiated EDH-
type relaxation and in vivo treatments did not show acute
toxicity, although we found a KCa3.1-dependent reduction of HR.
Compared with 13b (Lamoral-Theys et a l., 2010) that served
as a templa te for st ructu ra l modifica t ions, compounds RA-2,
RA-3, a n d RA-4, in wh ich t wo of t h e t h r ee 3-flu oro-4-
hydroxybenzoyloxymethyl subst ituents in 13b were conserved,
showed inhibitory act ivity. RA-2 with both substituents in the
1,3 posit ion was equally poten t in inhibit ing KCa3.1 (RA-2:
17 nM versus 13b: 19 nM) (Oliván-Viguera et a l., 2013). In line
with the not ion tha t RA-2 is a pan-nega tive KCa2/3 modulator,
all three subtypes of KCa2 channels were inhibited by RA-2 at
nanomolar concentrat ions, a lthough the IC50 value was higher
for RA-2 (2 nM) than for 13b (360 pM) in the case of hKCa2.3.
The st ructurally very simila r compounds RA-3 and RA-4 with
both substituents in the 1,2 and 1,4- positions, respect ively,
were also found to be potent KCa3.1 inhibitors. A major change
in the structure such as the absence of an additional 3-fluoro-4-
hydroxybenzoyloxymethyl substituent (as in RA-1), the sub-
stitut ion of the hydroxyl groups by acetamido groups on the
benzoic acid moiet ies (as in RA-5), or the introduct ion of a
hydroxymethyl subst ituent in the 5-position of the centra l
aromatic core (as in RA-6) gave lower log P va lues but caused
a loss of inhibitory efficacy. Thus, regarding the structure-
activity relat ionship, this suggested tha t the intactness of the
aromatic core as a lipophilic spacer and the presence of at least
two 3-fluoro-4-hydroxybenzoyloxymethyl branches were cr it i-
ca l for maintaining inhibitory efficacy. A change in the relat ive
position of the two 3-fluoro-4-hydroxybenzoyloxymethyl branches
had no major consequences with log P values (4.7) similar to
RA-2.
Together, the three structurally similar compounds, RA-2,
RA-3, and RA-4 were identified as potential pharmacophores for
pan-negative modulation of KCa2/3 channels that had a better
chemical profile with a lower molecular weight of 414 Da (RA-2,
RA-3, and RA-4) and lower log P values of 4.7 than the starting
compound 13b (mol. wt. 5 582; log P 5 6.0), suggesting in vivo
utility.
Simila r t o 13b, RA-2 acted as a nega t ive-ga t ing modula tor
as concluded from the substan t ia lly more poten t inh ibit ion
a t nanomola r Ca 21 and the an tagonism (relief of channel
inh ibit ion ) by the posit ive-ga t ing modula tor , SKA-31. St ruc-
tu ra lly, the nega t ive-ga t ing modula t ion by RA-2 and it s
Fi g. 4. Systemic cardiovascular act ions of RA-2 in
mice. (A) Telemetr ic 24 hour measurements of mean
ar ter ia l blood pressure (MAP) after in traper itonea l
in ject ions of 30 mg/kg (n = 4, exper iments) RA-2 or
vehicle (n = 6, exper iments) in to a tota l of 4 WT mice.
(B) HR lower ing effects of RA-2. (C) and (D) HR-
lower ing act ions of 30 mg/kg RA-2 (n = 3, exper iments
on three mice) were absent in KCa3.1
2 /2 mice. Black
and white par t s of the y-axis indicate dark and light
phases. Arrow indica tes t ime of inject ion (t = 0). Data
points a re mean 6 S.E.M. Horizonta l lines above or
below data points indica te sta t ist ica l significant dif-
ference from vehicle; *P , 0.05, Student ’s t test .















an tagon ism by the posit ive-ga t ing modula tor , SKA-31, cou ld
occur a t t he in ter fa ce of Ca M and the cytosolic C-t ermina l
Ca M-bin din g dom a in of t h e ch a n n els . In deed, dock in g
exper imen t s using co-crysta ls of CaM a nd the C-termina l
CaM-binding dom ain of KCa2.2 (Zhang et a l., 2012) revea led
tha t NS309 and 1-EBIO tha t a re st ruct u ra lly rela t ed to
SKA-31 bind in the in ter fa ce between the CAM and the
CAMBD to keep the channel in the open sta t e. However , we
do not wish to exclude tha t other a llost er ic effect s may
accoun t for the funct iona l an ta gon ism observed here. Re-
ga rding select ivity, micromola r concen t r a t ions of RA-2 did
not in t er fere with (block or act iva te) a ser ies of members of
dist an t ly rela t ed K1 channel families, suggest ing consider -
able select ivity for KCa2/3 over other K
1 channels.
The utility of RA-2 as a new tool and/or drug candidate for in
vivo use was demonst rated by the results of the present ex vivo
and in vivo experiments on freshly isola ted PCAEC and
coronary arteries. The patch-clamp exper iments showed that
endogenous KCa2 and KCa3.1 currents in PCAEC were fully
inhibited by RA-2, in this regard simila r to 13b. The results
from myography on PCAs showed that similar to 13b (Oliván-
Viguera et a l., 2013) RA-2 did not modulate basal tone,
suggesting that KCa2/3 channels were not essentially involved
in the control of basal arterial tone at least under these ex vivo
conditions. Agonist-induced EDH-type relaxations independent
of nitric oxide are known to require the activation of KCa2/3
channels and subsequent smooth muscle hyperpolarization in
many vascular beds (Edwards et al., 2010). Here, we found that
RA-2 inhibited BK-induced EDH-type relaxation in the presence
of the vasospasmic agent, U46619. This inhibition was almost
complete and the small RA-2–resistant relaxation could be ex-
plained by the contribution of other endothelium-derived relaxing
factor s such as eicosa noids, a s shown previou sly (F issltha ler
et a l., 1999). Nonetheless, these resu lt s showed tha t KCa2/3
activation by BK-induced endothelia l stimulation was a critically
step in EDH-type relaxation in strongly precontracted PCA, as
also suggested previously by others (Ge et al., 2000). However,
the specific contributions of KCa2/3 to this response were not
elucidated thus far. Regarding the potency of inhibition by RA-2,
it was noteworthy that RA-2 was more efficient than the more
lipophilic template 13b that did not produce significant in-
hibition of BK-induced relaxation of PCAs in the presence of the
vasospamic U46619 in our previous study (Oliván-Viguera et al.,
2013).
Our telemetry in freely moving mice showed that the
animals tolera ted the RA-2 inject ions well a t a dosage of up to
100 mg/kg per day (h ighest dose tested). There were no signs
of acute toxicity. Altera t ions of ar ter ia l pressure were not
Fi g. 5. Pharmacokinetics of RA-2. (A) RA-2 plasma calibration curve with concentrat ions ranging from 10 nM to 1 mM (r2 = 0.9995). (B) RA-2 plasma
concentrations following intraperitoneal application of 30 mg/kg (n = 3, mice). (C) Tissue concentrat ions 1 hour after intraperitoneal administrat ion of
RA-2 30 mg/kg (n = 3, mice). (D) Time course of tissue concentrations after intraperitoneal administration of RA-2 30 mg/kg (n = 3, mice). Data points are mean 6 S.D.















evident , and therefore acute systemic KCa2/3 inhibit ion by
RA-2 appeared to be safe. However , it should be noted tha t
RA-2 was cleared from the circu la t ion rapidly, presumably via
hydrolysis by plasma and hepa t ic esterases. Nonetheless,
RA-2 entered the brain and skeletal muscle where t issue
concentrat ions reached values clearly above IC50 values within
the first 2 hours after administ rat ion.
Albeit blood pressure changes were not evident , a single
dose of RA-2 (30 or 100 mg/kg) produced an appreciable
decrease in HR, which was apparent after in ject ion and more
pronounced dur ing the end of the act ivity phase and the
rest ing phase ( D145 beats per minute). An obvious in-
terpreta t ion of these da ta is that th is bradycardia might be an
adapta t ion to an increase of tota l per iphera l resistance—
caused by endothelia l KCa2/KCa3 inhibit ion in resistance size
ar ter ies—and baroreceptor act iva t ion to lower cardiac output
and to mainta in pressure constant .
In addit ion to expression in neurons and arteries, expression
of KCa2 channels—in particular of the KCa2.2 subtype—have
been reported in atrial myocytes (Tuteja et al., 2005; Li et al.,
2009) and the atrioventricular node (Zhang et al., 2008). Indeed,
blockers of KCa2 have been suggested to serve as antiarrhythmic
drugs by prolonging repolarization times and thereby action
potential duration, finally terminating atrial fibrillation (Diness
et al., 2010). Thus, one alternative explanation for the lower HR
might be tha t cardiac KCa2 inhibit ion by RA-2 caused pro-
longat ion of act ion potential durat ion in at ria l t issues. An
addit iona l explanat ion could be that RA-2 a ltered t ransmission
t ime a t the level of the at rioventr icula r node.
Nonetheless, the precise mechanism by which RA-2 pro-
duced bradycardia remains to be identified in fu ture studies. At
present, we do not wish to exclude that by esterase-media ted
hydrolysis RA-2 could be a source of diphenols with potential
antioxidat ive proper ties. However, the observat ion that RA-2–
induced bradycardia was not seen in KCa3.1-deficient mice
suggested that an inhibit ion of KCa3.1 channels, bu t not of KCa2
channels, was mechanist ically involved in the WT situat ion.
In conclusion, we identified RA-2 as a selective pan-negative-
gat ing modulator of KCa2/3 channels with nanomolar potency
and ex vivo and in vivo act ivity in coronary ar tery endothelium
and in systemic cardiovascular regulat ion. We presumed RA-2
to be a novel pan-negative-gat ing modulator of KCa2/3 channels
with a drug-like profile. Moreover, RA-2 can be considered
a useful tool compound to study physiologic and pathophysi-
ologica l roles of KCa2/3 channels in vit ro or in vivo and may be
of therapeutic utility to treat hypotension and undesired hy-
peremia as well as chronic inflammation and disorders charac-
terized by abnormal cell proliferation.
Acknowledgments
The authors thank Dr. Eduardo Romanos-Alfonso and Susana
Murillo-Pola from the Unit of Funct ional Evaluat ions of the IACS for
excellent technica l support (telemetry).
Authorship Contributions
Participated in research design: Oliván-Viguera , Wulff, Valero,
Gálvez, Díaz-de-Villegas, Badorrey, Köhler .
Conducted exper iments: Oliván-Viguera , Valero, Lar ía , Murillo,
Coleman, Brown, Badorrey, Köhler .
Performed data analysis: Oliván-Viguera, Valero, Murillo, Badorrey,
Köhler.
Wrote or contr ibuted to the wri ting of the manuscr ipt: Oliván-
Viguera, Gálvez, Díaz-de-Villegas, Wulff, Badorrey, Köhler .
References
Adelm a n J P , Ma ylie J , a n d Sa h P (2012) Sm a ll-con du ct a n ce Ca 21 -a ct iva t ed
K1 channels: Form and funct ion. Annu Rev Physiol 74:245–269.
Alda J O, Valero MS, Pereboom D, Gros P, and Garay RP (2009) Endothelium-
independent vasorelaxa t ion by the select ive alpha estrogen receptor agonist propyl
pyrazole t r iol in ra t aor t ic smooth muscle. J Pharm Pharmacol 61:641–646.
Ataga KI and Stocker J (2009) Senicapoc (ICA-17043): a potent ia l therapy for the
prevent ion and t rea tment of hemolysis-associated complicat ions in sickle cell
anemia . Expert Opin Investig Drugs 18:231–239.
Brähler S, Kaistha A, Schmidt VJ , Wölfle SE, Busch C, Kaistha BP, Kacik M,
Hasenau AL, Grgic I, and Si H et a l. (2009) Genet ic deficit of SK3 and IK1 channels
disrupts the endothelium-der ived hyperpolar izing factor vasodila tor pathway and
causes hyper tension. Circulation 119:2323–2332.
Cao YJ and Houamed KM (1999) Act iva t ion of recombinant human SK4 channels by
meta l cat ions. FEBS Lett 446:137–141.
Chantôme A, Pot ier-Cartereau M, Clarysse L, Fromont G, Marionneau-Lambot S,
Guéguinou M, Pagès J C, Collin C, Oullier T, and Girault A et al. (2013) Pivota l role
of the lipid Raft SK3-Orai1 complex in human cancer cell migrat ion and bone
metastases. Cancer Res 73:4852–4861.
Coleman N, Brown BM, Oliván-Viguera A, Singh V, Olmstead MM, Valero MS,
Köhler R, and Wulff H (2014) New posit ive Ca21 -act iva ted K1 channel ga t ing
modula tors with select ivity for KCa3.1. Mol Pharmacol 86:342–357.
D’Alessan dro G, Cat a la no M, Sciacca luga M, Ch ece G, Cipr ian i R, Rosito M,
Gr ima ldi A, La ur o C, Can tore G, and San tor o A et a l. (2013) KCa3.1 ch ann els a re
involved in th e infilt r a t ive beh avior of glioblast oma in vivo. Cel l Death Dis 4:
e773.
Damkjaer M, Nielsen G, Bodendiek S, Staehr M, Gramsbergen J B, de Wit C, J ensen
BL, Simonsen U, Bie P, and Wulff H et al. (2012) Pharmacological act ivat ion of
Fi g. 6. Possibly metabolites of RA-2 found in liver homogena te. Note that the parent compound, RA-2, was not found in the liver .















KCa3.1/KCa2.3 channels produces endothelia l hyperpolar ization and lowers blood
pressure in conscious dogs. Br J Pharmacol 165:223–234.
Devor DC, Singh AK, Frizzell RA, and Bridges RJ (1996) Modulat ion of Cl- secret ion
by benzimidazolones. I. Direct act ivat ion of a Ca21 -dependent K1 channel. Am J
Physiol 271:L775–L784.
Díez-Barra E, García-Martínez JC, Merino S, del Rey R, Rodríguez-López J , Sánchez-
Verdú P, and Tejeda J (2001) Synthesis, characterization, and optical response of di-
polar and non-dipolar poly(phenylenevinylene) dendrimers. J Org Chem 66:5664–5670.
Diness J G, Sørensen US, Nissen JD, Al-Shahib B, J espersen T, Grunnet M, and Hansen
RS (2010) Inhibition of small-conductance Ca21-activated K1 channels terminates and
protects against atrial fibrillation. Circ Arrhythm Electrophysiol 3:380–390.
Edwards G, Félétou M, and Weston AH (2010) Endothelium-der ived hyperpola r ising
factors and associated pa thways: a synopsis. Pflugers Arch 459:863–879.
Ellinor PT, Lunet ta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, Sinner MF, de
Bakker PI, Mueller M, and Lubitz SA et a l. (2010) Common variants in KCNN3 are
associa ted with lone at r ia l fibr illa t ion. Nat Genet 42:240–244.
Engbers J D, Anderson D, Asmara H, Rehak R, Mehaffey WH, Hameed S, McKay BE,
Kruskic M, Zamponi GW, and Turner RW (2012) Intermedia te conductance
calcium-act iva ted potassium channels modula te summation of para llel fiber input
in cerebellar Purkinje cells. Proc Natl Acad Sci USA 109:2601–2606.
Félétou M, Köhler R, and Vanhout te PM (2010) Endothelium-der ived vasoact ive
factors and hyper tension: possible roles in pathogenesis and as trea tment targets.
Curr Hypertens Rep 12:267–275.
Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R (1999)
Cytochrome P450 2C is an EDHF synthase in coronary ar ter ies. Nature401:493–497.
Ge ZD, Zhang XH, Fung PC, and He GW (2000) Endothelium-dependent hyperpo-
la r iza t ion and relaxat ion resistance to N(G)-nit ro-L-arginine and indomethacin in
coronary circula t ion . Cardiovasc Res 46:547–556.
Grgic I, Eichler I, Heinau P, Si H, Brakemeier S, Hoyer J , and Köhler R (2005)
Select ive blockade of the intermedia te-conductance Ca21 -act iva ted K1 channel
suppresses prolifera t ion of microvascular and macrovascula r endothelia l cells and
angiogenesis in vivo. Arter ioscler Thromb Vasc Biol 25:704–709.
Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J , Müller A, Kaistha A, Schmidt
C, and Raman G et al. (2009) Renal fibrosis is at tenuated by targeted disruption of
KCa3.1 potassium channels. Proc Natl Acad Sci USA 106:14518–14523.
Grissmer S, Nguyen AN, Aiyar J , Hanson DC, Mather RJ , Gutman GA, Karmilowicz
MJ , Auperin DD, and Chandy KG (1994) Pharmacologica l character iza t ion of five
cloned voltage-ga ted K1 channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably
expressed in mammalian cell lines. Mol Pharmacol 45:1227–1234.
Hougaard C, Hammami S, Eriksen BL, Sørensen US, J ensen ML, St røbæ k D,
and Christophersen P (2012) Evidence for a common pharmacologica l interact ion
site on KCa2 channels providing both select ive act ivat ion and select ive inhibit ion of
the human KCa2.1 subtype. Mol Pharmacol 81:210–219.
Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman J P, and Maylie J (1997) A
human intermedia te conductance ca lcium-act ivated potassium channel. Proc Natl
Acad Sci USA 94:11651–11656.
Jenkins DP, Strøbæk D, Hougaard C, Jensen ML, Hummel R, Sørensen US, Christophersen
P, and Wulff H (2011) Negative gat ing modulat ion by (R)-N-(benzimidazol-2-yl)-
1,2,3,4-tet rahydro-1-naphthylamine (NS8593) depends on residues in the inner pore
vestibule: Pharmacological evidence of deep-pore gat ing of KCa2 channels. Mol
Pharmacol 79:899–909.
Kau sha l V, Koeber le P D, Wa ng Y, a n d Sch lich ter LC (2007) The Ca 21 -a ct iva t ed
K1 channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent
neurodegeneration. J Neurosci 27:234–244.
Köhler M, Hirschberg B, Bond CT, Kinzie J M, Marr ion NV, Maylie J , and Adelman
J P (1996) Small-conductance, calcium-act iva ted potassium channels from mam-
malian brain . Science 273:1709–1714.
Köhler R, Degenhardt C, Kühn M, Runkel N, Paul M, and Hoyer J (2000) Expression
and funct ion of endothelia l Ca21 -act ivated K1 channels in human mesenter ic ar-
tery: A single-cell reverse t ranscr iptase-polymerase cha in react ion and elect ro-
physiologica l study in situ . Circ Res 87:496–503.
Köhler R, Kaistha BP, and Wulff H (2010) Vascular KCa-channels as therapeutic targets
in hypertension and restenosis disease. Expert Opin Ther Targets 14:143–155.
Köhler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A, Grgic I, Kämpfe D, Si H,
and Wibawa J et al. (2003) Blockade of the intermediate-conductance calcium-activated
potassium channel as a new therapeutic strategy for restenosis. Circulation 108:1119–1125.
Lam J , Coleman N, Garing AL, and Wulff H (2013) The therapeut ic potent ia l of
small-conductance KCa2 channels in neurodegenera t ive and psychia t r ic diseases.
Expert Opin Ther Targets 17:1203–1220.
Lambert sen KL, Gramsbergen J B, Sivasaravanaparan M, Ditzel N, Sevelsted-Møller
LM, Oliván-Viguera A, Rabjerg M, Wulff H, and Köhler R (2012) Genet ic KCa3.1-
deficiency produces locomotor hyperact ivity and a ltera t ions in cerebra l monoamine
levels. PLoS ONE 7:e47744.
Lamoral-Theys D, Pot t ier L, Kerff F , Dufrasne F, Prout ière F , Wauthoz N, Neven P,
Ingrassia L, Antwerpen PV, and Lefranc F et a l. (2010) Simple di- and tr ivanilla tes
exhibit cytosta t ic proper t ies toward cancer cells resistant to pro-apoptot ic st imuli.
Bioorg Med Chem 18:3823–3833.
Li N, Timofeyev V, Tuteja D, Xu D, Lu L, Zhang Q, Zhang Z, Singapuri A, Alber t TR,
and Rajagopal AV et al. (2009) Ablat ion of a Ca 21 -act iva ted K1 channel (SK2
channel) result s in act ion poten t ia l prolonga t ion in a t r ia l myocytes and at r ia l fi-
br illa t ion. J Physiol 587:1087–1100.
Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and
computat iona l approaches to est imate solubility and permeability in drug discov-
ery and development set t ings. Adv Drug Del iv Rev 46:3–26.
Meseguer V, Karashima Y, Talavera K, D’Hoedt D, Donovan-Rodríguez T, Viana F,
Nilius B, and Voets T (2008) Transient receptor poten t ia l channels in sensory
neurons are ta rgets of the ant imycot ic agent clotr imazole. J Neurosci 28:576–586.
Milkau M, Köh ler R, a n d de Wit C (2010) Cr ucia l im por t a n ce of t h e endot h elia l
K1 ch a nn el SK3 a n d conn exin 40 in a r t er iola r dila t ion s dur in g skelet a l m u scle
con t r act ion . FASEB J 24:3572–3579.
Mishra RC, Belke D, Wulff H, and Braun AP (2013) SKA-31, a novel act iva tor of SKCa
and IKCa channels, increases coronary flow in male and female ra t hear t s. Car-
diovasc Res 97:339–348.
Oliván-Viguera A, Valero MS, Murillo MD, Wulff H, García-Otín AL, Arbonés-Mainar
J M, and Köhler R (2013) Novel phenolic inhibitors of small/intermediate-conductance
Ca21 -activated K1 channels, KCa3.1 and KCa2.3. PLoS ONE 8:e58614.
Radtke J , Schmidt K, Wulff H, Köhler R, and de Wit C (2013) Act iva t ion of KCa3.1 by
SKA-31 induces ar ter iola r dila ta t ion and lowers blood pressure in normo- and
hyper tensive connexin40-deficient mice. Br J Pharmacol 170:293–303.
Rosa J C, Galanakis D, Ganellin CR, Dunn PM, and J enkinson DH (1998) Bis-quinolinium
cyclophanes: 6,10-diaza-3(1,3),8(1,4)-dibenzena-1,5(1,4)- diquinolinacyclodecaphane
(UCL 1684), the fir st na nomolar , non-pept idic blocker of the apamin-sensit ive
Ca 21 -act ivat ed K1 channel. J Med Chem 41:2–5.
Ruggieri P, Mangino G, Fioretti B, Catacuzzeno L, Puca R, Ponti D, Miscusi M, Franciolini
F, Ragona G, and Calogero A (2012) The inhibition of KCa3.1 channels activity reduces
cell motility in glioblastoma derived cancer stem cells. PLoS ONE 7:e47825.
Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J , Köhler R,
and Wulff H (2009) Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of
KCa2 and KCa3.1 potassium channels, potentiates the endothelium-der ived hyper-
polar izing factor response and lowers blood pressure. Mol Pharmacol 75:281–295.
Shakkot ta i VG, do Carmo Costa M, Dell’Orco J M, Sankaranarayanan A, Wulff H,
and Paulson HL (2011) Early changes in cerebella r physiology accompany motor
dysfunct ion in the polyglutamine disease spinocerebellar a taxia type 3. J Neurosci
31:13002–13014.
Soder RP, Parajuli SP, Hristov KL, Rovner ES, and Petkov GV (2013) SK channel-selective
opening by SKA-31 induces hyperpolarization and decreases contractility in human uri-
nary bladder smooth muscle. Am J Physiol Regul Integr Comp Physiol 304:R155–R163.
St røbæ k D, Brown DT, J enkins DP, Chen YJ , Coleman N, Ando Y, Chiu P, J ørgensen
S, Demnitz J , and Wulff H et a l. (2013) NS6180, a new KCa3.1 channel inhibitor
prevents T-cell act iva t ion and inflammat ion in a ra t model of inflammatory bowel
disease. Br J Pharmacol 168:432–444.
Taylor MS, Bonev AD, Gross TP, Eckman DM, Brayden J E, Bond CT, Adelman J P,
and Nelson MT (2003) Altered expression of small-conductance Ca21 -act iva ted K1
(SK3) channels modulates ar ter ia l tone and blood pressure. Circ Res 93:124–131.
Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, and Bowles DK (2008) Loca l
delivery of the KCa3.1 blocker , TRAM-34, prevents acute angioplasty-induced
coronary smooth muscle phenotypic modula t ion and limit s stenosis. Arter ioscler
Thromb Vasc Biol 28:1084–1089.
Toyama K, Wulff H, Chandy KG, Azam P, Raman G, Saito T, Fujiwara Y, Matt son
DL, Das S, and Melvin J E et al. (2008) The in termediate-conductance ca lcium-
act ivated potassium channel KCa3.1 contr ibutes to a therogenesis in mice and
humans. J Cl in Invest 118:3025–3037.
Tuteja D, Xu D, Timofeyev V, Lu L, Sharma D, Zhang Z, Xu Y, Nie L, Vázquez AE,
and Young J N et al. (2005) Different ia l expression of small-conductance Ca21 -ac-
t ivated K
1
channels SK1, SK2, and SK3 in mouse at r ia l and ventr icu la r myocytes.
Am J Physiol Heart Circ Physiol 289:H2714–H2723.
Valero MS, Pereboom D, Barcelo-Bat llory S, Brines L, Garay RP, and Alda J O (2011)
Protein kinase A signa lling is involved in the relaxant responses to the select ive
b-oest rogen receptor agonist diarylpropionit r ile in ra t aor t ic smooth muscle in
vit ro. J Pharm Pharmacol 63:222–229.
Van Der Velden J , Sum G, Barker D, Koumoundouros E, Barcham G, Wulff H, Cast le
N, Bradding P, and Snibson K (2013) KCa3.1 channel-blockade a t tenuates airway
pathophysiology in a sheep model of chronic asthma. PLoS ONE 8:e66886.
Vandorpe DH, Shmukler BE, J iang L, Lim B, Maylie J , Adelman J P, de Franceschi L,
Cappellini MD, Brugnara C, and Alper SL (1998) cDNA cloning and funct ional
character iza t ion of the mouse Ca21 -ga ted K1 channel, mIK1. Roles in regula tory
volume decrease and erythroid different ia t ion. J Biol Chem 273:21542–21553.
Wei AD, Gutman GA, Aldr ich R, Chandy KG, Grissmer S, and Wulff H (2005) In-
terna t iona l Union of Pharmacology. LII. Nomenclature and molecula r rela t ion-
ships of calcium-act iva ted potassium channels. Pharmacol Rev 57:463–472.
Werkman TR, Kawamura T, Yokoyama S, Higashida H, and Rogawski MA (1992)
Charybdotoxin, dendrotoxin and mast cell degranula ting pept ide block the voltage-
act ivated K1 current of fibroblast cells stably t ransfected with NGK1 (Kv1.2) K1
channel complementary DNA. Neuroscience 50:935–946.
Wulff H and Cast le NA (2010) Therapeut ic potent ia l of KCa3.1 blockers: an overview
of recent advances, and promising trends. Expert Rev Cl in Pharmacol 3:385–396.
Wulff H, Gutman GA, Cahalan MD, and Chandy KG (2001) Delinea t ion of the
clot r imazole/TRAM-34 binding site on the in termediate conductance ca lcium-
act ivated potassium channel, IKCa1. J Biol Chem 276:32040–32045.
Wulff H and Köhler R (2013) Endothelia l small- and intermediate-conductance KCa
channels: an update on their pharmacology and usefulness as cardiovascula r tar -
gets. J Cardiovasc Pharmacol 61:102–112.
Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier J M, and Shakkottai V
(2007) Modulators of small- and intermedia te-conductance calcium-activated potas-
sium channels and their therapeutic indications. Curr Med Chem 14:1437–1457.
Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, and Chandy KG (2000) Design of
a potent and selective inhibitor of the intermediate-conductance Ca21-activated K1 channel,
IKCa1: A potential immunosuppressant. Proc Natl Acad Sci USA 97:8151–8156.
Zhang M, Pasca l J M, Schumann M, Armen RS, and Zhang J F (2012) Ident ifica t ion
of t h e fu n ct ion a l bin din g pocket for com pou n ds t a r get in g sm a ll-con du ct a n ce
Ca21 -act ivated potassium channels. Nat Commun 3:1021.
Zhang Q, Timofeyev V, Lu L, Li N, Singapuri A, Long MK, Bond CT, Adelman J P,
and Chiamvimonvat N (2008) Funct iona l roles of a Ca21 -act ivated K1 (SK2)
channel in a tr ioventr icula r nodes. Circ Res 102:465–471.
Addr ess cor r espondence t o: Ralf Köhler, Unidad de Invest igación Trasla-
ciona l, Institu to Aragonés de Ciencias de la Salud (I1 CS), Hospita l Universitar io
Miguel Servet, Paseo Isabel la Católica , 1-3, 50009-Zaragoza , Spain . E-mail:
rkohler.iacs@aragon.es






 Journals on F
ebruary 22, 2018
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
